Richard Katz, MD
Cardiovascular Disease · San Diego, CANPI 1548332539
Payments from drug & device makers
Across 128 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$389
- Astellas Pharma US Inc$255
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$228
- Johnson & Johnson$221
- Abbott$207
- Pfizer$165
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,52994%
- Education$1536%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $389 |
| Astellas Pharma US Inc | 7 | $255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $228 |
| Johnson & Johnson | 15 | $221 |
| Abbott | 7 | $207 |
| Pfizer | 8 | $165 |
| Sanofi-aventis U.S. LLC | 9 | $158 |
| Amgen | 8 | $143 |
| Impulse Dynamics (USA) Inc. | 2 | $137 |
| Amarin Pharma, Inc. | 4 | $84 |
| E.r. Squibb & Sons, L.L.C. | 4 | $79 |
| Biotronik Inc. | 4 | $69 |
| Stryker | 1 | $62 |
| Philips North America LLC | 2 | $54 |
| Boehringer Ingelheim | 3 | $52 |
| Medtronic | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Merck | 2 | $42 |
| Boston Scientific | 2 | $38 |
| Irhythm Technologies, Inc. | 1 | $36 |
| Arbor Pharmaceuticals, Inc. | 2 | $30 |
| Baxter Healthcare | 1 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Bardy Diagnostics, Inc. | 2 | $19 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$209
How this compares
$2,682 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $190,326 |
| XareltoRivaroxaban | 33 | $43,363 |
| MultaqDronedarone Hcl | 18 | $25,949 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 27 | $16,725 |
| EdarbiAzilsartan Medoxomil | 19 | $12,214 |
| CorlanorIvabradine Hcl | 11 | $7,797 |
| Potassium Chloride | 197 | $5,909 |
| Atorvastatin Calcium | 519 | $5,452 |
| Losartan Potassium | 270 | $3,425 |
| Nebivolol Hcl | 25 | $2,806 |
| Ezetimibe | 66 | $2,759 |
| Metoprolol Succinate | 197 | $2,619 |
| Valsartan | 71 | $2,347 |
| Levothyroxine Sodium | 130 | $2,036 |
| Metoprolol Tartrate | 269 | $1,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $165 | $190,326141 claims |
| Johnson & JohnsonXarelto | $221 | $43,36333 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi | $30 | $28,93946 claims |
| Sanofi-aventis U.S. LLCMultaq | $158 | $25,94918 claims |
| AmgenCorlanor | $143 | $7,79711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$10.2M
- Michael WilkinsonSan Diego$1.9M
- William PennySan Diego$829K
- Ajit RaisinghaniSan Diego$695K
- Kevin KingSan Diego$598K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.